EN DE
Watch Scope Fluidics SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Scope Fluidics SA (SCP) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Scope Fluidics SA stock PLN 42.03, price PLN 143, that is 70.6% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLSCPFL00018

SF Scope Fluidics SA logo Thin data Nov 8, 2026

Scope Fluidics SA

SCP · WAR
Very expensive, weak quality

Our calculation puts a fair price 71% below what the stock costs today.

Low debt
Changed on Oct 29: PLN 35.73 → PLN 42.03
Fair value 42.03 PLN · Strongly overvalued
Quality 39/100
Weak Growth (revenue 3y −37.2 %/yr in PLN)
Negative free cash flow
Trails peers (2/7)
Narrow moat 8/100 · thin data
Thin data
Watch Scope Fluidics SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

243.25 PLN 64.06 PLN Fair Value 42.03 PLN Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 64.06 PLN – 243.25 PLN · fair‑value band 27.74 PLN – 52.54 PLN · the 142.80 PLN price screens above the 42.03 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Scope Fluidics in your weekly email

Every Wednesday you see whether Scope Fluidics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.

Stock analysis

Scope Fluidics SA (SCP) currently trades at 142.80 PLN, while our model-based Fair Value estimate is 42.03 PLN, 71% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: 27.74 PLN (bear) to 52.54 PLN (bull), the price of 142.80 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Scope Fluidics SA reported revenue of 100K PLN in FY2025 versus 0 PLN in FY2021. Reported net income was −46.4M PLN in FY2025.

Key figures

Market cap 452M PLN (≈ $116M) Micro · EPS (TTM) −16.49 PLN · Return on equity −38.0% · Return on assets (EBIT) 17.1% (5-year average) · Operating margin −36,725% · Revenue (TTM) −517K PLN · Revenue growth (YoY) −95.1% · Free cash flow −59.5M PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −71%, SCP screens richer than that median.

Fair Value models

Bear 27.74 PLN Fair Value 42.03 PLN Bull 52.54 PLN
Price 142.80 PLN · Downside -70.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 27.74 PLN 42.03 PLN 52.54 PLN 54
All 1 models by family
Asset-Based
NCAV (Graham) 27.74 PLN 42.03 PLN 52.54 PLN 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 81
How calm the share price moves, does not count
Price momentum 47
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 48
Distance to the 52-week high, does not count
New shares 55
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−23.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.2%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−31.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.5% (2015) → −47,282.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SCP screens overvalued: fair value 71% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Scope Fluidics SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 125 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −70.6% · Bottom 25%
Profitability
Return on assets −23.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −95.1% · Bottom 25%
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.71× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 15
HEALTH (low debt)96 · sector 95
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥150.29 ¥165.32 +10% vs SCP
IQVIA Holdings IQV $278.84 $299.58 +7% vs SCP
Illumina, Inc ILMN $220.78 $234.44 +6% vs SCP
Thermo Fisher Scientific Inc TMO $721.63 $686.04 −5% vs SCP
Danaher Corporation DHR $235.12 $209.18 −11% vs SCP
IDEXX Laboratories, Inc IDXX $706.65 $496.48 −30% vs SCP
Mettler-Toledo International Inc MTD $1,762 $655.06 −63% vs SCP
Agilent Technologies, Inc A $180.17 $64.53 −64% vs SCP
Lonza Group LONN CHF 659.40 CHF 153.50 −77% vs SCP
Waters Corporation WAT $476.70 $91.26 −81% vs SCP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Scope Fluidics SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Scope Fluidics SA Fair Value". https://www.fairvalue-calculator.com/stock/SCP

Frequently asked questions

Is Scope Fluidics SA (SCP) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 42.03 PLN versus a price of 142.80 PLN, about 71% lower (overvalued).
What is the fair value of SCP?
Our model-based fair value for Scope Fluidics SA is 42.03 PLN (as of Nov 8, 2026), built from audited fundamentals. The current price: 142.80 PLN.
What is the quality score of SCP?
Scope Fluidics SA has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Scope Fluidics SA (SCP)?
Our model-based price target is the fair value of 42.03 PLN (as of Nov 8, 2026) from 1 valuation models. Cautious scenario 27.74 PLN, optimistic scenario 52.54 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Scope Fluidics SA stock forecast for 2026?
Our models put fair value at 42.03 PLN, about 71% lower versus a price of 142.80 PLN (overvalued). Cautious scenario 27.74 PLN, optimistic scenario 52.54 PLN. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Scope Fluidics SA (SCP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Scope Fluidics SA it is 42.03 PLN per share (as of Nov 8, 2026), against a price of 142.80 PLN. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Scope Fluidics SA stock overvalued or undervalued in 2026?
As of Nov 8, 2026, SCP trades above its calculated fair value: price 142.80 PLN, fair value 42.03 PLN, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SCP?
No. The price is what the market pays today (142.80 PLN); the fair value is what the company's own numbers justify (42.03 PLN). For Scope Fluidics SA the two are 100.77 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Scope Fluidics SA worth?
The market values Scope Fluidics SA at about 452M PLN (market capitalisation, as of Nov 8, 2026). Per share that is 142.80 PLN; our models calculate a fair value of 42.03 PLN per share.
What do the bullish and bearish scenarios say about SCP?
Our models span a range for Scope Fluidics SA: cautious scenario 27.74 PLN, base 42.03 PLN, optimistic 52.54 PLN per share (as of Nov 8, 2026, price 142.80 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Scope Fluidics SA (SCP)?
Balance-sheet figures for Scope Fluidics SA (as of Nov 8, 2026): return on equity −38.0%, debt of 0.07 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is SCP from its 52-week high?
Scope Fluidics SA trades at 142.80 PLN, about 9% below its 52-week high of 156.40 PLN and 26% above the low of 113.00 PLN (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 42.03 PLN is for.
Which stocks are comparable to Scope Fluidics SA?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Scope Fluidics SA stock attractive at the current price?
The data as of Nov 8, 2026: price 142.80 PLN, calculated fair value 42.03 PLN (−71%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SCP calculated?
We run Scope Fluidics SA through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 42.03 PLN builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Scope Fluidics SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Scope Fluidics SA (SCP)?
The closing price on Nov 9, 2026 was 142.80 PLN. Our model-based fair value is 42.03 PLN, about 71% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Scope Fluidics SA right now?
The price sits above even our optimistic bull case (52.54 PLN). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (27.74 PLN to 52.54 PLN) leaves room in how you read the outcome.

Key figures of Scope Fluidics SA

How large is the market capitalisation of Scope Fluidics SA (SCP)?
The market capitalisation of Scope Fluidics SA is 452M PLN (≈ $116M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Scope Fluidics SA (SCP)?
Earnings per share at Scope Fluidics SA are −16.49 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Scope Fluidics SA (SCP)?
The return on equity (ROE) of Scope Fluidics SA is −38.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Scope Fluidics SA (SCP)?
On an EBIT basis the return on assets of Scope Fluidics SA is 17.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Scope Fluidics SA (SCP)?
The operating margin of Scope Fluidics SA is −36,725% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much revenue does Scope Fluidics SA (SCP) generate?
Scope Fluidics SA generates revenue of −517K PLN (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How fast is revenue growing at Scope Fluidics SA (SCP)?
Revenue at Scope Fluidics SA is growing −95.1% versus a year earlier (3y avg −37.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Scope Fluidics SA (SCP) generate?
The free cash flow of Scope Fluidics SA is −59.5M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Scope Fluidics SA (SCP) hold?
Scope Fluidics SA holds more cash than debt, 75.7M PLN net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Scope Fluidics SA in the live analysis

One click puts Scope Fluidics SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.